Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.36 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.32 |
| ▸ | PTGIR | P43119 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17651946 | 0.79 | MAPK1 (0.35) | NOTUMHSD11B1 | |
| SCHEMBL10917397 | 0.75 | NOTUM (0.39) | NOTUMP2RX7RXRAGRIN1GRIN2B | |
| SCHEMBL6971146 | 0.72 | KDM4E (0.37) | NOTUM | |
| SCHEMBL10676751 | 0.72 | NOTUM (0.36) | NOTUMP2RX7 | |
| SCHEMBL8022922 | 0.69 | NOTUM (0.36) | NOTUMP2RX7 | |
| SCHEMBL6967504 | 0.69 | TGFBR1 (0.32) | — | |
| SCHEMBL7939502 | 0.68 | BACE1 (0.33) | — | |
| SCHEMBL7713293 | 0.68 | ALDH1A1 (0.40) | — | |
| SCHEMBL10916866 | 0.64 | CYP11B1 (0.31) | — | |
| SCHEMBL29566200 | 0.63 | KMO (0.40) | NOTUMKMOGRIN2BNMUR2CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155715-B1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | ALLERGAN INC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20100273814-A1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | SINHA SANTOSH C | 2010-10-28 | — | — | US | disclosed |
| EP-2155715-A1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | ALLERGAN, INC. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008141312-A1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | ALLERGAN, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273814-A1 | ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS | CYP11B2, TPMT, COXFA4L2 | MDM2 2614/4885NOTUM 1191/4885KMO 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.